BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 34578321)

  • 1. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.
    Jahan N; Ghouse SM; Martuza RL; Rabkin SD
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
    Hong B; Sahu U; Mullarkey MP; Kaur B
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus.
    Nguyen HM; Sah N; Humphrey MRM; Rabkin SD; Saha D
    J Vis Exp; 2021 May; (171):. PubMed ID: 34057449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
    Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
    Wang H; Borlongan M; Kaufman HL; Le U; Nauwynck HJ; Rabkin SD; Saha D
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
    Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
    Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
    Kang KD; Bernstock JD; Totsch SK; Gary SE; Rocco A; Nan L; Li R; Etminan T; Han X; Beierle EA; Eisemann T; Wechsler-Reya RJ; Bae S; Whitley R; Gillespie GY; Markert JM; Friedman GK
    Clin Cancer Res; 2022 Dec; 28(24):5419-5430. PubMed ID: 36239623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
    Zhang S; Rabkin SD
    Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
    [No Abstract]   [Full Text] [Related]  

  • 19. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
    Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
    Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.